These results are interesting since de novo pyrimidine synthesis has been recently reported as a novel vulnerability in the IDH1-mutant astrocytoma models and suggests the potential for combining RT with de novo pyrimidine synthesis inhibitors (35). This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).